Santaris Plans Phase II Trial of miRNA-Targeting HCV Drug
April 29, 2010
Santaris Plans Phase II Trial of miRNA-Targeting HCV Drug
The company has also decided to keep the drug in-house until it has collected data from a phase II study of hepatitis C-infected patients, at which point it will pursue partnerships.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Santaris Pharma to Begin Phase II Development of miRNA-Targeting HCV Drug
September 23, 2010 / Gene Silencing News - Santaris Sues Mirrx Founder Over Blockmir Technology
May 6, 2010 / Gene Silencing News - With Positive Phase II Data on HCV Drug, Santaris Aims for Another Clinical Trial by the Summer
April 26, 2012 / Gene Silencing News - Santaris to Present Phase IIa Data on HCV Drug
April 19, 2012 / Gene Silencing News - UNC Teams Uncovers How HCV Uses miR-122 to Survive
January 5, 2012 / Gene Silencing News